冠状病毒病(COVID-19)的诊断工具:CT与逆转录聚合酶链反应病毒核酸检测的比较
本综述评估了认为CT对COVID-19诊断敏感性远优于RT-PCR的多项报告,发现胸部CT临床效用有限,尤其对无症状患者和疾病早期筛查患者。结论认为CT对COVID-19敏感性有限且特异性低于RT-PCR,并存在暴露医务人员于SARS-CoV-2的风险,应作为补充诊断工具,尤其对出现症状的患者。
要点
- 胸部CT对COVID-19敏感性有限,特异性低于RT-PCR检测。
- CT临床效用有限,尤其对无症状及疾病早期筛查患者。
- 胸部CT应视为补充诊断工具,尤其用于出现症状的患者。
核心结论
- CT对COVID-19敏感性有限且特异性低于RT-PCR检测,并存在暴露医务人员于SARS-CoV-2的风险。
- 胸部CT应视为补充诊断工具,尤其用于出现症状的患者。
研究设计与样本
- 综述,评估报告CT敏感性远优于RT-PCR的多项研究。
临床应用与阅片要点
- 胸部CT应视为补充诊断工具,尤其用于出现症状的患者。
- CT对无症状患者和疾病早期筛查患者的临床效用有限。
局限性
- CT对COVID-19敏感性有限且特异性低于RT-PCR检测。
- CT检查存在暴露医务人员于SARS-CoV-2的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. Multiple studies suggest CT should be a primary diagnostic tool for coronavirus disease (COVID-19) because they reported sensitivities with CT far superior to that of reverse transcriptase polymerase chain reaction (RT-PCR) testing. This review aimed to assess these reports and found chest CT to have a clinical utility that is limited, particularly for patients who show no symptoms and patients who are screened early in disease progression. CONCLUSION. CT has limited sensitivity for COVID-19 and a lower specificity than RT-PCR testing, and it carries a risk of exposing providers to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Chest CT should be considered a supplemental diagnostic tool, particularly for patients who show symptoms.
引用
- Waller JV, Kaur P, Tucker A, et al. Diagnostic Tools for Coronavirus Disease (COVID-19): Comparing CT and RT-PCR Viral Nucleic Acid Testing. AJR Am J Roentgenol. 2020. PMID: 32412790. doi:10.2214/AJR.20.23418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。